The new EU compass could support small companies to grow their market share across Europe, assisted by fewer regulatory ...

Lilly licenses sintilimab from Suzhou-based biotech Innovent Biologics ... and Dr Jill Biden. Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being ...

SAN FRANCISCO and SUZHOU, China, Jan. 16 ... Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

as it tries to carve out a share of a market currently dominated by Novo Nordisk and Eli Lilly. Mazdutide – a once-weekly injectable Innovent licensed from Lilly – was submitted to China's ...

SAN FRANCISCO and SUZHOU, China, Jan. 16, 2025 /PRNewswire/ -- Innovent ... Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD ...

SY-009 is a novel SGLT1 inhibitor, that is not listed at home or abroad. With the permission of Eli Lilly Company, Suzhou Yabao Pharmaceutical Research and Development Co., Ltd., initiated the ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.